Bioaffinity Technologies, Inc. current report, Q2 FY2026

Business Context and Reporting Period

Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2026
Reporting Period: Event date of June 16, 2026
Business Context: The Company is a Delaware corporation focused on lung health screening and early detection. It is classified as an emerging growth company.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K reports a corporate event rather than financial results.

Material Changes

No material financial changes versus a prior comparable period are reported in this filing. The document serves to announce a specific upcoming corporate event.

Guidance, Outlook, and Management Commentary

  • Upcoming Event: The Company announced a webinar scheduled for July 21, 2026.
  • Topic: The webinar will feature clinical experts discussing emerging approaches to lung health screening and early detection.
  • Target Audience: The discussion focuses on veterans at increased risk for lung cancer and other respiratory diseases.
  • Exhibits: A press release detailing the event is attached as Exhibit 99.1.

Investor Verification Checklist

  • Verify the date and registration details for the July 21, 2026 webinar.
  • Review the attached press release (Exhibit 99.1) for specific clinical data or partnership details.
  • Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
  • Check subsequent filings for financial results, as this 8-K contains no financial data.